CONMED Corporation (NASDAQ:CNMD) posted its quarterly earnings data on Thursday. The medical technology company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.41 by $0.01, Bloomberg Earnings reports. The business had revenue of $190.10 million for the quarter, compared to analyst estimates of $187.13 million. CONMED Corporation had a net margin of 2.02% and a return on equity of 8.38%. CONMED Corporation’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.41 earnings per share. CONMED Corporation updated its FY17 guidance to $1.85-1.90 EPS.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, October 5th. Stockholders of record on Friday, September 15th were issued a dividend of $0.20 per share. The ex-dividend date was Thursday, September 14th. This represents a $0.80 annualized dividend and a dividend yield of Infinity.

In related news, Director Jo Ann Golden sold 3,000 shares of CONMED Corporation stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $50.00, for a total value of $150,000.00. Following the completion of the sale, the director now directly owns 19,782 shares in the company, valued at approximately $989,100. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.62% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at

CNMD has been the subject of several recent analyst reports. BidaskClub cut shares of CONMED Corporation from a “sell” rating to a “strong sell” rating in a report on Sunday, August 20th. Needham & Company LLC reaffirmed a “buy” rating and issued a $57.00 target price on shares of CONMED Corporation in a report on Friday, September 1st. Zacks Investment Research raised shares of CONMED Corporation from a “sell” rating to a “hold” rating in a report on Tuesday. KeyCorp reaffirmed a “hold” rating on shares of CONMED Corporation in a report on Friday, August 25th. Finally, TheStreet raised shares of CONMED Corporation from a “c+” rating to a “b-” rating in a report on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company’s stock. CONMED Corporation currently has an average rating of “Hold” and an average price target of $52.50.

About CONMED Corporation

CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.

Earnings History for CONMED Corporation (NASDAQ:CNMD)

Receive News & Ratings for CONMED Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.